CONTEXT: Epidermal growth factor receptor (EGFR) is overexpressed in up to 80% of colorectal and endometrial carcinomas. Deletions of the polyA tract in the 3' untranslated region (3' UTR) have been reported in microsatellite instability-high (MSI-H) colonic carcinomas, but their impacts on EGFR expression and downstream pathways are unclear. This phenomenon has not been reported in other MSI-H tumors. OBJECTIVE: To assess the 3' UTR polyA tract of EGFR in both endometrial and colorectal carcinomas and the mutational status of EGFR downstream pathways. DESIGN: Ninety-eight colorectal carcinomas and 47 endometrial carcinomas were included. EGFR 3' UTR polyA status was detected by capillary electrophoresis and Sanger sequencing. EGFR gene expression, EGFR copy numbers, and KRAS and BRAF mutation status were analyzed accordingly. RESULTS: The 3' UTR polyA tract was deleted in 18 of 23 (78%) MSI-H versus 0 of 24 microsatellite-stable endometrial carcinomas (P < .001). Similar observations were seen in colorectal carcinomas, in which 29 of 36 (81%) MSI-H, 1 of 62 (1.6%) microsatellite instability-low, and none of the microsatellite-stable tumors harbored the deletion (P < .001). A moderate increase in EGFR mRNA level was observed in endometrial carcinomas with 3' UTR polyA deletions versus those with wild-type polyA tract. Amplification of the EGFR gene was not observed. Deletions in polyA tract do not seem to affect the frequency of KRAS and BRAF mutations. CONCLUSIONS: Deletions of EGFR 3' UTR polyA are frequent in endometrial and colorectal carcinomas, are confined almost exclusively to MSI-H tumors, and do not affect KRAS and BRAF mutations.
CONTEXT: Epidermal growth factor receptor (EGFR) is overexpressed in up to 80% of colorectal and endometrial carcinomas. Deletions of the polyA tract in the 3' untranslated region (3' UTR) have been reported in microsatellite instability-high (MSI-H) colonic carcinomas, but their impacts on EGFR expression and downstream pathways are unclear. This phenomenon has not been reported in other MSI-H tumors. OBJECTIVE: To assess the 3' UTR polyA tract of EGFR in both endometrial and colorectal carcinomas and the mutational status of EGFR downstream pathways. DESIGN: Ninety-eight colorectal carcinomas and 47 endometrial carcinomas were included. EGFR 3' UTR polyA status was detected by capillary electrophoresis and Sanger sequencing. EGFR gene expression, EGFR copy numbers, and KRAS and BRAF mutation status were analyzed accordingly. RESULTS: The 3' UTR polyA tract was deleted in 18 of 23 (78%) MSI-H versus 0 of 24 microsatellite-stable endometrial carcinomas (P < .001). Similar observations were seen in colorectal carcinomas, in which 29 of 36 (81%) MSI-H, 1 of 62 (1.6%) microsatellite instability-low, and none of the microsatellite-stable tumors harbored the deletion (P < .001). A moderate increase in EGFR mRNA level was observed in endometrial carcinomas with 3' UTR polyA deletions versus those with wild-type polyA tract. Amplification of the EGFR gene was not observed. Deletions in polyA tract do not seem to affect the frequency of KRAS and BRAF mutations. CONCLUSIONS: Deletions of EGFR 3' UTR polyA are frequent in endometrial and colorectal carcinomas, are confined almost exclusively to MSI-H tumors, and do not affect KRAS and BRAF mutations.
Authors: Reade B Roberts; Lu Min; M Kay Washington; Sandra J Olsen; Stephen H Settle; Robert J Coffey; David W Threadgill Journal: Proc Natl Acad Sci U S A Date: 2002-01-29 Impact factor: 11.205
Authors: S Kondo; S Kubota; T Eguchi; T Hattori; T Nakanishi; T Sugahara; M Takigawa Journal: Biochem Biophys Res Commun Date: 2000-11-11 Impact factor: 3.575
Authors: P E de Wit; S Moretti; P G Koenders; M A Weterman; G N van Muijen; B Gianotti; D J Ruiter Journal: J Invest Dermatol Date: 1992-08 Impact factor: 8.551
Authors: Ziqiang Yuan; Joongho Shin; Andrew Wilson; Sanjay Goel; Yi-He Ling; Naseem Ahmed; Higinio Dopeso; Minaxi Jhawer; Shannon Nasser; Cristina Montagna; Kenneth Fordyce; Leonard H Augenlicht; Lauri A Aaltonen; Diego Arango; Thomas K Weber; John M Mariadason Journal: Cancer Res Date: 2009-09-29 Impact factor: 12.701
Authors: Rajyalakshmi Luthra; Keyur P Patel; Neelima G Reddy; Varan Haghshenas; Mark J Routbort; Michael A Harmon; Bedia A Barkoh; Rashmi Kanagal-Shamanna; Farhad Ravandi; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Rajesh R Singh Journal: Haematologica Date: 2013-10-18 Impact factor: 9.941
Authors: Nasrin Sarafan-Vasseur; David Sefrioui; David Tougeron; Aude Lamy; France Blanchard; Florence Le Pessot; Frédéric Di Fiore; Pierre Michel; Stéphane Bézieau; Jean-Baptiste Latouche; Thierry Frebourg; Richard Sesboüé Journal: BMC Cancer Date: 2013-04-08 Impact factor: 4.430
Authors: Manuela Pinheiro; Carla Pinto; Ana Peixoto; Isabel Veiga; Paula Lopes; Rui Henrique; Helena Baldaia; Fátima Carneiro; Raquel Seruca; Ian Tomlinson; Michal Kovac; Karl Heinimann; Manuel R Teixeira Journal: Br J Cancer Date: 2015-08-06 Impact factor: 7.640